These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 26995558

  • 1. Investigation of Neurokinin-1 Receptor Antagonism as a Novel Treatment for Chronic Bronchitis in Dogs.
    Grobman M, Reinero C.
    J Vet Intern Med; 2016 May; 30(3):847-52. PubMed ID: 26995558
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Canine chronic bronchitis.
    Rozanski E.
    Vet Clin North Am Small Anim Pract; 2014 Jan; 44(1):107-16. PubMed ID: 24268336
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
    Ramsey DS, Kincaid K, Watkins JA, Boucher JF, Conder GA, Eagleson JS, Clemence RG.
    J Vet Pharmacol Ther; 2008 Dec; 31(6):538-43. PubMed ID: 19000277
    [Abstract] [Full Text] [Related]

  • 11. Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine.
    Sharun K, Jambagi K, Arya M, Aakanksha, Chaithra SN, Patel PK, Dixit SK, Dhama K.
    Arch Razi Inst; 2021 Nov; 76(5):1175-1182. PubMed ID: 35355772
    [Abstract] [Full Text] [Related]

  • 12. Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs.
    Hay Kraus BL.
    J Am Vet Med Assoc; 2014 Nov 01; 245(9):1015-20. PubMed ID: 25313812
    [Abstract] [Full Text] [Related]

  • 13. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs.
    Alvillar BM, Boscan P, Mama KR, Ferreira TH, Congdon J, Twedt DC.
    Vet Anaesth Analg; 2012 Mar 01; 39(2):201-5. PubMed ID: 22103569
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neurokinin-1 receptor expression and antagonism by the NK-1R antagonist maropitant in canine melanoma cell lines and primary tumour tissues.
    Borrego JF, Huelsmeyer MK, Pinkerton ME, Muszynski JL, Miller SA, Kurzman ID, Vail DM.
    Vet Comp Oncol; 2016 Jun 01; 14(2):210-24. PubMed ID: 24751104
    [Abstract] [Full Text] [Related]

  • 18. The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.
    de la Puente-Redondo VA, Siedek EM, Benchaoui HA, Tilt N, Rowan TG, Clemence RG.
    J Small Anim Pract; 2007 Feb 01; 48(2):93-8. PubMed ID: 17286662
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The anti-inflammatory action of maropitant in a mouse model of acute pancreatitis.
    Tsukamoto A, Ohgoda M, Haruki N, Hori M, Inomata T.
    J Vet Med Sci; 2018 Mar 24; 80(3):492-498. PubMed ID: 29343664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.